[REVISION HISTORY]
Turkey GLP-1 weight-loss injection guidance
Updated 1 time since CLSTR started tracking revisions of this situation.
What changed
2026-07-30 08:23 UTC → 2026-08-12 09:20 UTC ·
added
removed
Turkey GLP‑1 weight‑loss GLP-1 weight-loss injection guidance
In late July 2026, a Turkish internal‑medicine specialist Dr. Ebru Hacer Inal, an internal-medicine specialist, warned that GLP‑1 GLP-1 and GIP receptor agonist injections marketed for weight loss must be initiated and monitored by a physician. She highlighted While noting these metabolic treatments can improve type-2 diabetes and fatty-liver disease, she emphasized the need for pre‑treatment pre-treatment examinations of the gallbladder, pancreas pancreas, and eyes, alongside regular blood‑test monitoring, and cautioned blood-test monitoring. She noted that common side effects such as nausea, vomiting, constipation like nausea and abdominal bloating usually subside over time. She also noted that constipation typically subside, but stopping the medication can lead to weight regain, emphasizing continued healthy eating and activity. Two days later, a regain. Following this, nutrition specialist Dyt. Gamze Ustabaş explained that discontinuing GLP‑1 these injections triggers a biological appetite rebound, especially particularly for carbohydrates, making portion control difficult. An additional expert as the body attempts to restore lost energy. In a separate discussion, Prof. Dr. Mesut Başak described an alternative, non‑dietary method—a pressure‑applying alternative method using an abdominal corset—that can corset to induce early satiety and modest weight loss, while warning of contraindications and satiety, though he warned it is unsuitable for those with reflux or gastritis. By mid-August, General Surgery Specialist Assoc. Prof. Dr. Sönmez Ocak raised concerns regarding the risks increasing non-prescription use of extreme diets. Both experts reiterated second-generation injections. While these drugs can lead to a weight loss of approximately 20 percent, Dr. Ocak warned that the importance rapid loss of professional medical guidance before starting or stopping any weight‑loss regimen. subcutaneous fat can cause facial sagging and an aged appearance. He further cautioned that without sufficient protein and vitamin support, users risk muscle and bone loss, and highlighted potential severe risks including pancreatitis, gallstones, and thyroid cancer.
Versions
- 2026-08-12 09:20 UTC Turkey GLP-1 weight-loss injection guidance
- 2026-07-30 08:23 UTC Turkey GLP‑1 weight‑loss injection guidance
Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.